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Background: Endovascular stent-graft (ESG) repair of abdominal aortic aneurysm (AAA) has emerged as an alternative to
open surgery. The role of ESG in patients with challenging medical and anatomic problems remains an area of general
debate. This study reviews an experience with stent grafts to treat patients with AAA and atheromatous embolization
syndrome (AES) presenting with chronic distal embolization (CDE).
Methods: Over a 5-year period 660 patients with AAA were treated with aortic stent grafts. Patients with AAA and
ischemic ulcerations or toe gangrene due to CDE despite palpable foot pulses were investigated for successful aneurysm
exclusion, resolution of ischemic symptoms, complications and survival. Follow-up averaged 15.3 14.9 months (range,
1 to 60 months).
Results: Nineteen patients had AAA and manifestations of CDE. The population (16 males/3 females) had a mean age of
79 7 years and mean aneurysm diameter of 5.5 cm. Renal insufficiency was present in 5/19 (26 %). Ischemia presented
as ischemic ulcers (16/19 [84.2%]) or toe gangrene (3/19 [15.8%]). Stent grafts included 6 aortouniiliac and 13
bifurcated devices. Exclusion was achieved in all but 2 patients who had type II lumbar endoleaks. At 30-day
postoperative follow-up, mortality was 0 % and resolution of CDE/ischemia was noted in 2 of 19 (10.5%) patients. Eight
of 9 patients with follow-up of 1 year had complete resolution of their ischemic symptoms, with no recurrent
manifestations of AES. Complications included progression of renal insufficiency over an 18-month period in 1 patient
and an unstable expanding pararenal aortic neck in 1 patient. Foot ischemia persisted at 1 year in a patient with severe
coexisting thoracic aortic disease despite successful AAA exclusion. Six (31.6%) patients died during a mean follow-up of
15.3 months from causes unrelated to their AAA.
Conclusion: On the basis of this experience, stent-graft repair of AAA and CDE may be an effective strategy to prevent
future embolization. Recognition of coexisting thoracic aortic disease is essential. ESG does not address the extremely
high morbidity and mortality from cardiovascular causes in this population. (J Vasc Surg 2004;40:424-9.)Since the accurate relationship between embolism and
a diseased atherosclerotic aorta was described in 1945 by
Flory,1 atheromatous embolization syndrome (AES) has
been associated with a high risk of morbidity and mortali-
ty.2-5 Embolic debris including thrombus, platelet fibrin
material, or cholesteral crystals dislodge and produce isch-
emia in various distal arterial beds. This results in the
recognition of this entity by various specialties. Treatment
options including medical,6-11 surgical,12-13 and endovas-
cular therapy 14-19 have focused on supportive and symp-
tomatic treatment of the end organ as well as prevention of
further embolization from occurring.
With the introduction of endovascular stent-graft
(ESG) repair of abdominal aortic aneurysm (AAA), its
application in the treatment of patients with challenging
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debate. Stent-graft repair of abdominal aortic aneurysms in
patients with atheromatous embolization syndrome(AES)
offers the added benefit of preventing the escape of throm-
bus or plaque debris from the circulation in addition to
protecting the patient from rupture. This report reviews
our experience with endovascular stent graft repair of ab-
dominal aortic aneurysm in patients with atheromatous
embolization syndrome(AES) presenting with chronic dis-
tal embolization (CDE).
METHODS
Since January 1999, 660 patients underwent endovas-
cular stent graft repair of an infrarenal abdominal aortic
aneurysm at Mount Sinai Medical Center in New York
City. Nineteen of these patients had ischemic ulcerations or
toe gangrene due to atheromatous embolization despite
palpable pedal pulses. All patients underwent preoperative
imaging with multislice CT angiography of the chest abdo-
men and pelvis, digital subtraction angiography of the
abdominal aorta with lower extremities and transthoracic
echocardiography. Thirteen patients were treated with
modular bifurcated devices, and six patients received aor-
touniiliac devices with femoral-femoral bypass and occlu-
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stent-graft devices used included 17 Talent-LPS
(Medtronic Vascular, Santa Rosa, Calif) and 2 AneuRx
(Medtronic Vascular, Santa Rosa, Calif).
This study was performed in conjunction with our
investigator-sponsored investigational device exemption
(IDE) examining the use of the Talent endovascular stent
graft in the treatment of infrarenal AAA in the high-risk
patient. The experimental protocol and informed consent
were approved by the Institutional Review Board of the
Mount Sinai School of Medicine. All subjects gave in-
formed consent.
Follow-up. Mean follow-up was 15.3  15 months
(range, 1 to 60 months). Follow-up, consisting of a physi-
cian’s office visit, plain abdominal radiographs, and three-
phase contrast-enhanced CT angiography was performed
at 1 month, 6 months, 12 months, and yearly thereafter.
Each patient was investigated for successful aneurysm ex-
clusion, resolution of ischemic symptoms, complications,
and survival. In the follow-up period all patients were
treated with antiplatelet therapy. Anticoagulation therapy
was not included in the management of this patient popu-
lation, in the postoperative period unless indicated for a
coexisting medical issue.
RESULTS
The Table shows the characteristics of the study popu-
lation. Nineteen (2.9%) of the 660 patients with AAAs
treated during this time period demonstrated evidence of
AES. The population of 16 men and 3 women had a mean
age of 79  7 years and mean aneurysm diameter of 5.5
cm. Five of 19 patients (26%) had a serum creatinine greater
than 2.0 mg/dL.
Fig 1. A, Photograph of a foot on presentation, with to
a patient with AAA and palpable pedal pulses. B, Followin
toes with no further evidence of embolization.All patients had manifestations of embolization develop
within a month of evaluation. The ischemic manifestations
presented as ischemic ulcers (16/19 [84.2%]) or toe gan-
grene (3/19 [15.8%]). Associated pain—cyanosis as well as
tenderness on examination—was present in all patients.
Mottling and livedo reticularis were associated in a majority
of cases and included the soles of the feet, the buttocks, and
the thighs, although the findings for the latter 2 were less
pronounced than the findings in the feet. Lower extremity
mottling was bilateral in all patients. In approximately a
third of the cases a similar event had occurred previously
(Fig 1).
grene as manifestation of atheromatous embolization in
t-graft exclusion of AAA and amputation of gangrenous
Characteristics of 19 patients with AAA and









Heart disease 6 31.6




Hypercoagulable state 0 0.0
Patient age (mean  SD) was 79.16  7.3 y. Of the 19 patients, 16 were
men and 3 were woman.
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary
disease; CVA, cerebrovascular accident.
*Creatinine  2.0.e gan
g sten
AAA
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of AAA was technically successful in all cases (Fig 2).
Complete aneurysm exclusion was achieved in 17 of 19
patients. The 2 cases with persistent flow within the aneu-
rysm sac had type II endoleaks. Endoleaks were identified
on the patients’ 1-month CT scans, 1 from lumbar arteries
and 1 from a patent inferior mesenteric artery and paired
lumbar arteries. The IMA endoleak persisted and was ap-
parent on the 6-month CT scan. There were no procedural
or perioperative deaths within 30 days of the aneurysm
repair. There were no clinically evident episodes of intraop-
erative embolization. Resolution of pedal ischemic mani-
Fig 2. Computed tomography scan of patient with an A
to treatment and (B) following stent-graft repair of the
Fig 3. Computed tomography angiogram of a patient at
large type I endoleak.festations occurred in 2 of 19 patients (10.5%) (Fig 2). One
patient underwent toe amputation for gangrene resulting
from the initial embolic episode.
More than 30-day follow-up. During the mean fol-
low-up of 15.3  15 months (range, 1-60), 6 of the 19
(31.6%) patients died. No deaths were aneurysm related.
Death resulted from myocardial infarction in 2 patients and
advanced bladder cancer in 1 patient. The remaining 3
patients’ families refused autopsies. Complications in-
cluded a patient who had progressive dilatation of the
proximal aortic neck, which ultimately resulted in a proxi-
mal type I endoleak; the patient is awaiting open aneurysm
nd manifestations atheromatous embolization (A) prior
demonstrated full exclusion of the aneurysm sac.
r showing degeneration of the proximal aortic neck withAA a1 yea
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insufficiency; the creatinine rose to 5.4 mg/dL from a
preprocedural level of 3.2 mg/dL. This patient demon-
strated evidence of disease in the descending thoracic aorta.
Nine patients had 1-year follow-up data available. Eight of
these 9 patients had complete resolution of ischemic symp-
toms with no recurrent manifestations of atheromatous
embolization. One patient had persistent ischemic manifes-
tations at 1-year follow-up with full exclusion of the infra-
renal AAA. This patient also demonstrated concomitant
atherosclerotic disease present in the thoracic aorta (Fig 4).
No patients required amputation during the follow-up
period.
DISCUSSION
Embolization from AAA is relatively uncommon. One
minor limitation of this study is that the population de-
scribed did not have histologic confirmation of microem-
bolization. However, AES can usually be diagnosed on
clinical grounds. Although we cannot determine with ab-
solute certainty that the embolization was from the aneu-
rysm, the clinical manifestations in the presence of palpable
foot pulses, with complete imaging of the vascular system
failing to demonstrate another source of potential emboli-
Fig 4. Aortic angiogram demonstrating atherosclerotic
aorta as well as the infrarenal aneurysmal aorta.zation in most patients, suggests the aneurysm as a poten-
tial source. The resolution of the ischemic manifestations in
the majority of patients also suggests that the source may in
fact have been the aneurysm.
The optimal form of therapy for patients with AAAs
and AES is not clearly defined. Shames et al15 demon-
strate no further embolic events in patients after place-
ment of a stent graft for aortoiliac disease that included
aneurysms and plaque lesions. Amputation was limited
to the toe and related to ischemia prior to treatment.
While the numbers are small, our experience is similar to
that of Shames and colleagues. In patients who were
followed for 1 year, 89% experienced healing of their
ischemic ulcerations and were free of further emboliza-
tion. Given the high mortality in this patient population,
the question arises whether aortic stent grafting provides
any clear benefit. In this study, recurrent foot ischemic
episodes were uncommon and the procedure was per-
formed with minimal complication. Freedom from re-
current manifestations of pedal ischemia suggests that
some benefit may be provided with endograft exclusion
of aortic aneurysms when other embolic sources are not
present. A similar group of patients managed medically
with similar follow-up is unavailable for comparison, and
se and potential source of embolization in the thoracicdisea
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There is no information about the utility of repairing
small aneurysms to prevent distal embolization; how-
ever, if patients fail medical management, stent grafting
may be an effective alternative. In the current study, the
size of the aneurysms warranted treatment based on
rupture risk. The high mortality rate among these pa-
tients is due to advanced cardiovascular disease and
illustrates the necessity of an aggressive cardiovascular
risk factor program for all patients with atheromatous
embolization.
No clinically evident embolization occurred secondary
to the procedures. All devices were deployed following
vascular control at the femoral level in an effort to avoid
distal embolization. In addition, complete coverage of the
aorta from the renal arteries to the iliac bifurcation may
minimize surface area of exposed debris that may have
become unstable on device advancement. Embolization to
the internal iliac arteries with pelvic ischemic complications
is a potential risk but was not a problem in this study. The
progressive renal insufficiency that developed in 1 patient
may have occurred with procedural manipulation, but in
this patient the descending thoracic aorta was lined with
significant atheromatous debris. As the renal insufficiency
was a progressive decline over 18 months, we feel that the
thoracic aorta was a likely source of subsequent emboliza-
tion.
One patient had recurrent embolization following
treatment of an infrarenal aortic aneurysm. This patient had
evidence of coexisting thoracic aortic disease and thus
another potential source of embolization. The thoracic
aorta is a well-known source of embolization11,20 for which
there is no clear-cut superior medical therapy. Criado et
al21 describe a patient previously treated by open surgery
for an embolizing lesion of the thoracic aortic aorta. Fol-
low-up imaging demonstrated unstable characteristics of
that arterial segment, which was subsequently was success-
fully treated with a stent graft.
While no deaths occurred within the 30-day postoper-
ative period, there was a 31.6 % mortality within the mean
follow-up period of 15.3 months. The cause of death was
known in 3 patients. Two of these patients died of myocar-
dial infarction. This further supports previous studies iden-
tifying the poor prognosis of this patient population due to
myocardial infarction, stroke, or other cardiovascular
death.2,5
There are no randomized controlled trials of any
therapeutic intervention for patients with cholesterol
embolization, and no single treatment modality has been
associated with a favorable outcome in case series.
Clearly, the most important aspect of therapy is preven-
tion. Exclusion of the embolic source with stent-graft
placement can avoid recurrent episodes of ischemia and
amputation in patients with AAA and embolization.22,23
Further experience will be needed to determine whether
stent-graft repair of AAA with manifestations of athero-
matous embolization actually improves upon overall pa-
tient morbidity and survival. However, it should not beforgotten that this patient population dies of cardiovas-
cular causes; therefore, optimal risk factor modification
to prevent myocardial infarction, stroke, and the pro-
gression of atherosclerotic disease should be imple-
mented in every patient.20
CONCLUSION
On the basis of this experience, stent-graft repair of
AAA with manifestations of chronic distal embolization
may be an effective strategy to prevent future embolization.
Recognition of coexisting thoracic aortic disease is essential
to avoid further episodes of atheromatous embolization.
Endovascular stent grafting does not address the extremely
high morbidity and mortality from cardiovascular causes in
this patient population.
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